Lineage Cell Therapeutics

Lineage Cell Therapeutics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Lineage Cell Therapeutics (LCTX) as of Oct 31, 2026 is 30.60 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 127.13 % — a change of -75.93% (lower).

FCF Conversion

30.60 %

YoY

-75.93%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Lineage Cell Therapeutics is 2025 30.60 % . FCF Conversion Rate (FCF/EBITDA) of Lineage Cell Therapeutics was 2024 127.13 % . It decreases by -75.93% lower compared to the previous year.

The Lineage Cell Therapeutics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
74.30 USD
Jan 1, 2019
276.60 USD
Jan 1, 2020
95.97 USD
Jan 1, 2021
55.59 USD
Jan 1, 2022
-2.46 USD
Jan 1, 2023
136.09 USD
Jan 1, 2024
127.13 USD
Jan 1, 2025
30.60 USD
The Lineage Cell Therapeutics FCF Conversion history
YEARFCF ConversionYoY
30.60 %-75.93%
127.13 %-6.59%
136.09 %-5,634.76%
-2.46 %-104.42%
55.59 %-42.07%
95.97 %-65.30%
276.60 %+272.29%
74.30 %-53.39%
159.41 %-219.32%
-133.60 %-225.87%
106.14 %-1.75%
108.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lineage Cell Therapeutics Stock analysis

What does Lineage Cell Therapeutics do? Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lineage Cell Therapeutics stock

FCF Conversion Rate (FCF/EBITDA) of Lineage Cell Therapeutics is 30.60 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Lineage Cell Therapeutics changed from 127.13 % to 30.60 %, representing a -75.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Lineage Cell Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Lineage Cell Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Lineage Cell Therapeutics

All Key Metrics — Lineage Cell Therapeutics